Traditional blood filter manufacturing uses solvent-based hydrophilization, consuming large volumes of water, generating chemical wastewater, and emitting significant carbon. TTRI's SCF Process replaces solvents with supercritical CO₂, achieving hydrophilization through physical implantation under fully anhydrous, solvent-free conditions — a fundamental shift from chemical treatment. CO₂ is captured from the atmosphere and recycled in a closed loop with zero net emissions, eliminating all solvent use and wastewater generation. Per-unit cost drops by 57% and carbon emissions fall by over 80%. With global demand of approximately 120 million units per year, this technology creates substantial industrial value. Products are currently under quality verification at Taiwan Blood Donation Center.